Słabicki, Mikołaj
Kozicka, Zuzanna
Petzold, Georg
Li, Yen-Der
Manojkumar, Manisha
Bunker, Richard D.
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Sievers, Quinlan L.
Koeppel, Jonas https://orcid.org/0000-0003-1306-3994
Suchyta, Dakota
Sperling, Adam S.
Fink, Emma C.
Gasser, Jessica A.
Wang, Li R.
Corsello, Steven M. https://orcid.org/0000-0002-9929-3709
Sellar, Rob S.
Jan, Max
Gillingham, Dennis
Scholl, Claudia
Fröhling, Stefan
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Thomä, Nicolas H. https://orcid.org/0000-0003-2685-906X
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Article History
Received: 9 November 2019
Accepted: 29 April 2020
First Online: 3 June 2020
Competing interests
: B.L.E. has received research funding from Celgene and Deerfield and consulting fees from GRAIL. He serves on the scientific advisory boards for and holds equity in Skyhawk Therapeutics and Exo Therapeutics. E.S.F. is a founder and/or member of the scientific advisory board and equity holder of C4 Therapeutics and Civetta Therapeutics, and is a consultant to Novartis, AbbVie and Pfizer. N.H.T. receives funding from the Novartis Research Foundation and is a member of the scientific advisory board of Monte Rosa Therapeutics. The Fischer laboratory receives or has received research funding from Novartis, Deerfield and Astellas. S.F. has had a consulting or advisory role, received honoraria, research funding and/or travel/accommodation expenses funding from the following for-profit companies: Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca and Pfizer. R.B. is now an employee of Monte Rosa Therapeutics. S.M.C. and T.R.G. receive research funding from Bayer HealthCare. T.R.G. was formerly a consultant and equity holder in Foundation Medicine (acquired by Roche). T.R.G. also is a consultant to GlaxoSmithKline and is a founder of Sherlock Biosciences.